Intellia Therapeutics (NASDAQ:NTLA) Announces Quarterly Earnings Results

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) announced its earnings results on Thursday. The company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.08, Zacks reports. The business had revenue of $12.87 million for the quarter, compared to analyst estimates of $8.10 million.

Intellia Therapeutics Stock Performance

Shares of Intellia Therapeutics stock traded down $0.64 on Monday, reaching $9.45. The company had a trading volume of 2,998,270 shares, compared to its average volume of 3,289,680. The firm's 50 day moving average price is $10.85 and its two-hundred day moving average price is $15.55. Intellia Therapeutics has a 52-week low of $8.96 and a 52-week high of $33.28. The firm has a market cap of $962.47 million, a PE ratio of -1.74 and a beta of 1.80.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on NTLA shares. Morgan Stanley downgraded shares of Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $56.00 to $11.00 in a research note on Monday, January 27th. StockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a research note on Friday, November 8th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday. William Blair reiterated a "neutral" rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research report on Monday, November 18th. Finally, Oppenheimer lowered their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating on the stock in a research note on Monday, January 13th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.12.

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares of the company's stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders sold 29,000 shares of company stock valued at $352,551. Company insiders own 3.20% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.